SIBN Overview

Key Data

  • Open $29.24
  • Day Range 29.24 - 30.82
  • 52 Week Range 18.53 - 37.21
  • Market Cap $996.11M
  • Shares Outstanding 32.83M
  • Public Float 28.51M
  • Beta 1.04
  • Rev. per Employee $248.77K
  • P/E Ratio N/A
  • EPS -$1.43
  • Yield N/A
  • Dividend N/A
  • Ex-Dividend Date N/A
  • Short Interest 1.15M 07/15/21
  • % of Float Shorted 4.05%
  • Average Volume 243.76K

Performance

5 Day
  • 4.20%
1 Month
  • 3.28%
3 Month
  • -8.30%
YTD
  • 1.20%
1 Year
  • 55.74%

Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 8 Full Ratings

Recent News

  • MarketWatch
  • Dow Jones

Si-Bone stock price target cut to $37 from $42 at Needham

Aug. 3, 2021 at 6:00 a.m. ET by Tomi Kilgore

Si-Bone stock price target raised to $42 from $34 at Needham

May. 4, 2021 at 5:59 a.m. ET by Tomi Kilgore

Si-Bone stock price target raised to $35 from $28 at Needham

Dec. 16, 2020 at 5:56 a.m. ET by Tomi Kilgore

Si-Bone started at buy with $27 stock price target at SunTrust RH

Jan. 8, 2020 at 10:08 a.m. ET by Tomi Kilgore
Barron's

Beating the Market With Medical-Device Stocks

Feb. 13, 2019 at 12:38 p.m. ET by Barron's

Si-Bone started at overweight with $24 stock price target at Morgan Stanley

Nov. 12, 2018 at 12:44 p.m. ET by Tomi Kilgore
  • Other News
  • Press Releases

SI-Bone (SIBN) Receives a Buy from Needham

Aug. 3, 2021 at 5:55 a.m. ET on TipRanks.com

SI-Bone (SIBN) Receives a Buy from Bank of America Securities

Aug. 3, 2021 at 1:05 a.m. ET on TipRanks.com

Si-Bone (SIBN) Reports Q2 Loss, Tops Revenue Estimates

Aug. 2, 2021 at 5:45 p.m. ET on Zacks.com

Si-Bone (SIBN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Jul. 26, 2021 at 3:01 p.m. ET on Zacks.com

Si-Bone (SIBN) Reports Q1 Loss, Tops Revenue Estimates

May. 3, 2021 at 6:25 p.m. ET on Zacks.com

Morgan Stanley Believes SI-Bone (SIBN) Won’t Stop Here

Mar. 9, 2021 at 11:30 a.m. ET on SmarterAnalyst

Merrill Lynch Sticks to Their Buy Rating for SI-Bone (SIBN)

Mar. 9, 2021 at 8:55 a.m. ET on SmarterAnalyst

SI-Bone (SIBN) Gets a Buy Rating from Canaccord Genuity

Mar. 9, 2021 at 6:29 a.m. ET on SmarterAnalyst

Si-Bone (SIBN) Reports Q4 Loss, Tops Revenue Estimates

Mar. 8, 2021 at 6:45 p.m. ET on Zacks.com

Canaccord Genuity Believes SI-Bone (SIBN) Still Has Room to Grow

Feb. 5, 2021 at 4:28 a.m. ET on SmarterAnalyst

Needham Keeps Their Buy Rating on SI-Bone (SIBN)

Feb. 1, 2021 at 4:05 a.m. ET on SmarterAnalyst

These 3 “Strong Buy” Stocks Are Top Picks for 2021, Say Analysts

Jan. 17, 2021 at 12:42 p.m. ET on TipRanks.com

Canaccord Genuity Believes SI-Bone (SIBN) Still Has Room to Grow

Jan. 8, 2021 at 6:27 a.m. ET on SmarterAnalyst

Needham Believes SI-Bone (SIBN) Won’t Stop Here

Jan. 7, 2021 at 11:36 a.m. ET on SmarterAnalyst

Cantor Fitzgerald Believes SI-Bone (SIBN) Still Has Room to Grow

Dec. 23, 2020 at 4:04 a.m. ET on SmarterAnalyst

Canaccord Genuity Believes SI-Bone (SIBN) Won’t Stop Here

Dec. 17, 2020 at 6:15 a.m. ET on SmarterAnalyst

Needham Believes SI-Bone (SIBN) Won’t Stop Here

Dec. 16, 2020 at 5:35 a.m. ET on SmarterAnalyst

Morgan Stanley Believes SI-Bone (SIBN) Won’t Stop Here

Dec. 15, 2020 at 3:45 p.m. ET on SmarterAnalyst

Needham Believes SI-Bone (SIBN) Won’t Stop Here

Nov. 16, 2020 at 6:18 a.m. ET on SmarterAnalyst

SI-Bone (SIBN) Receives a Buy from Canaccord Genuity

Nov. 3, 2020 at 6:25 a.m. ET on SmarterAnalyst

SI-BONE Inc.

SI-BONE, Inc. engages in the provision of implantable devices used in the surgical treatment of the sacropelvic anatomy. It offers a proprietary minimally invasive surgical implant system, called iFuse, used to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that often causes severe lower back pain. The company was founded by Mark A. Reiley and Jeffrey W. Dunn on March 18, 2008 and is headquartered in Santa Clara, CA.